Регионарная цитратная антикоагуляция с применением 4%-ного раствора цитрата натрия


DOI: https://dx.doi.org/10.18565/nephrology.2023.2.57-61

Аветисян Э.А., Кострица Н.С.

ФГБУ НМИЦ кардиологии им. акад. Е.И. Чазова Минздрава РФ, Москва, Россия
Вопрос метода антикоагуляции во время различных экстракорпоральных процедур является актуальным ввиду возрастающей частоты применения этой процедуры врачами различных специальностей. Регионарная цитратная антикоагуляция (РЦА) имеет ряд преимуществ перед системной антикоагуляцией гепарином, в т.ч. большее время жизни фильтра при заместительной почечной терапии (ЗПТ), меньший риск кровотечений. С целью достижения максимальной эффективности и безопасности РЦА предложено много различных алгоритмов дозирования цитрата, из них одним из наиболее изученных является протокольная цитратная антикоагуляция с 4%-ным раствором цитрата натрия. Данный обзор литературы освещает основные исследования, в которых оценивали эффективность и безопасность применения данной методики. В настоящий момент результаты исследований позволяют профессиональным сообществам рекомендовать РЦА в качестве метода выбора при проведении продленной ЗПТ.
Ключевые слова: цитрат натрия, экстракорпоральная гемокоррекция, региональная цитратная антикоагуляция, заместительная почечная терапия
Полный текст статьи доступен
в "Библиотеке Врача"

Литература


  1. Deepa. C., Muralidhar K. Renal replacement therapy in ICU. J. Anaesthesiol. Clin. Pharmacol. 2012;28:386.

  2. Christopher W.M., James O.B. Dialysis. BMJ. 2014;348:bmj.g2–bmj.g2.

  3. Brandenburger T., Dimski T., Slowinski T., Kindgen-Milles D. Renal replacement therapy and anticoagulation. Best Pract. Res. Clin. Anaesthesiol. 2017;31:387–401.

  4. Schetz M. Anticoagulation in Continuous Renal Replacement Therapy. Eds. C. Ronco, R. Bellomo, G. La Greca. Contribut. Nephrol. 2001;132:283–303.

  5. Singh S. Anticoagulation during Renal Replacement Therapy. Indian J. Crit. Care Med. 2020;24:112–16.

  6. Frías A., et al. Efectividad de anticoagulación regional con citrato en terapia de reemplazo renal continua. Rev. Méd. Chile. 2022;150:283–88.

  7. Lenga I., Hopman W.M., O’Connell A.J., et al. Flexitrate regional citrate anticoagulation in continuous venovenous hemodiafiltration: a retrospective analysis. BMC. Nephrol. 2019;20:452.

  8. Buccione E., et al. Regional Citrate Anticoagulation and Systemic Anticoagulation during Pediatric Continuous Renal Replacement Therapy: A Systematic Literature Review. J. Clin. Med. 2022;11:3121.

  9. Rhee H., Berenger B., Mehta R.L., Macedo E. Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study. Am. J. Kidney Dis. 2021;78:550–9.e1.

  10. Poh C.B., et al. Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy – A Safe and Effective Low‐Dose Protocol. Nephrol. 2020;25:305–13.

  11. Kindgen-Milles D., Brandenburger T., Dimski T. Regional citrate anticoagulation for continuous renal replacement therapy: Curr. Opin. Crit. Care. 2018;24:450–54.

  12. Kellum J.A., Lameire N. For the KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part. 1). Crit. Care 2013;17:204.

  13. Shum H.-P., Kwan A.M.-C., Chan K.-C., Yan W.-W. The Use of Regional Citrate Anticoagulation Continuous Venovenous Hemofiltration in Extracorporeal Membrane Oxygenation. ASAIO J. 2014;60:413–18.

  14. Rajsic S., et al. Anticoagulation Strategies during Extracorporeal Membrane Oxygenation: A Narrative Review. J. Clin. Med. 2022;11:5147.

  15. Brogan T.V., Lequier L., Lorusso R. et al. Extracorporeal life support: the ELSO red book. 2017.

  16. Hosgood S.A., et al. Normothermic machine perfusion versus static cold storage in donation after circulatory death kidney transplantation: a randomized controlled trial. Nat. Med. 2023 Doi: 10.1038/s41591-023-02376-7.

  17. Oudemans-van Straaten H.M., Ostermann M. Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice. Crit. Care 2012;16: 249.

  18. Fisher R., et al. Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study. Ann. Intensive Care. 2022;12:29.

  19. Burry L.D., et al. Regional Citrate Anticoagulation for PrismaFlex Continuous Renal Replacement Therapy. Ann. Pharmacother. 2009;43:1419–25.

  20. Morgera S., et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit. Care Med. 2009;37:2018–24.

  21. .Joannidis M. Regional citrate anticoagulation – Finally on its way to standardization? Crit. Care Med. 2009;37:2128–29.

  22. Arepally G.M. Heparin-induced thrombocytopenia. Blood. 2017;129:2864–72.

  23. Wiegele M., et al. Thrombin Generation and Platelet Function in ICU Patients Undergoing CVVHD Using Regional Citrate Anticoagulation. Front. Med. 2021;8:680540.

  24. Tang X., et al. Application of regional citrate anticoagulation in patients at high risk of bleeding during intermittent hemodialysis: a prospective multicenter randomized controlled trial. J. Zhejiang Univ.-Sci. 2022;23:931–42.

  25. Zhang W., et al. Continuous renal replacement therapy without anticoagulation in critically ill patients at high risk of bleeding: A systematic review and meta‐analysis. Semin. Dial. 2021;34:196–208.

  26. Zarbock A., et al. Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2020;324:1629.

  27. Stucker F., et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit. Care 2015;19:91.

  28. Feng X., Deng L., Zhang Y., Chang L. Regional citrate versus heparin anticoagulation in continuous renal replacement therapy in critically ill patients: a Meta-analysis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32:982–87.

  29. Liu C., Mao Z., Kang H., Hu J., Zhou F. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Crit. Care. 2016;20:144.

  30. Cointault O., et al. Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions. Nephrol. Dial. Transplant. 2004;19:171–78.

  31. Morgera S., et al. Metabolic Complications during Regional Citrate Anticoagulation in Continuous Venovenous Hemodialysis: Single-Center Experience. Nephron Clin. Pract. 2004;97:131–36.

  32. Bai M., et al. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intens. Care Med. 2015;41:2098–110.

  33. Fernández S.N., et al. Citrate Anticoagulation for CRRT in Children: Comparison with Heparin. BioMed Res. Int. 2014;2014:1–7.

  34. Kramer L., et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients: Crit. Care Med. 2003;31:2450–55.

  35. Persic V., et al. Regional citrate anticoagulation for continuous renal replacement therapy in newborns and infants: Focus on citrate accumulation. Artif. Organs. 2020;44:497–503.

  36. Bakker A.J., Boerma E.C., Keidel H., et al. Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium. Clin. Chem. Lab. Med. 2006;CCLM:44.

  37. 37.Rhee H., Berenger B., Mehta R.L., Macedo E. Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study. Am. J. Kidney Dis. 2021;78: 550–9.e1.

  38. Khadzhynov D., et al. Efficacy and complications of regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients with COVID-19. J. Crit. Care. 2022;67:126–31.

  39. Botan E., et al. Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation in Children with Liver Dysfunction/Failure. J. Trop. Pediatr. 2022;68:fmac048.

  40. Hu F., Sun Y., Bai K., Liu C. Clinical application of regional citrate anticoagulation for continuous renal replacement therapy in children with liver injury. Front. Pediatr. 2022;10:847443.

  41. Schultheiß C., et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit. Care. 2012;16:R162.

  42. Peng B., Lu J., Guo H., et al. Regional citrate anticoagulation for replacement therapy in patients with liver failure: A systematic review and meta-analysis. Front. Nutr. 2023;10:1031796.

  43. Saner F.H., et al. Efficacy and safety of regional citrate anticoagulation in liver transplant patients requiring post-operative renal replacement therapy. Nephrol. Dial. Transplant. 2012;27:1651–57.


Об авторах / Для корреспонденции

Аветисян Эрик Арменович – врач-кардиолог ПРИТ отдела неотложной кардиологии ФГБУ НМИЦ кардиологии им. акад. Е.И. Чазова Минздрава РФ.
Адрес: 121552, Москва, ул. Академика Чазова, 15а. ORCID: 0000-0002-9660-9851
Кострица Наталья Сергеевна – врач-кардиолог, ординатор ПРИТ отдела неотложной кардиологии ФГБУ НМИЦ кардиологии им. акад. Е.И. Чазова Минздрава РФ.
Адрес: 121552, Москва, ул. Академика Чазова, 15а; e-mail: nataliakostritsaffm@gmail.com. ORCID: 0000-0002-8746-8727


Похожие статьи

К содержанию номера

Бионика Медиа